Related Experiment Video
Updated: Feb 7, 2026
Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
Published on: February 10, 2023
An observational study of apatinib mesylate in treating advanced non-small cell lung cancer with unknown driving
Shaoshuang Fan1, Yuhuan Zou, Yifeng Wang
1Graduate School of North China, University of Science and Technology, Tangshan 063000, China.
Purpose:
To investigate the efficacy and safety of apatinib mesylate (AM) in treating advanced non-small cell lung cancer (aNSCLC) with wild or unknown epidermal growth factor receptor (w/nEGFR).
Methods:
A total of 34 w/nEGFR -aNSCLC patients who failed chemotherapy from August 2015 to April 2017 were administered orally AM (425 mg/d) as primary treatment and observed their progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR), as well as related adverse events.
Results:
Efficacy was evaluable in 30 cases, with median PFS (mPFS) 3.75 months (95% CI 0.648-6.852), ORR 20%, and DCR 73.33%. The main adverse reactions included hypertension (52.94%), hand-foot syndrome (52.94%), proteinuria (44.12%), and fatigue (41.18%); no drug-related death occurred. The efficacy correlation analysis showed that Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1 (p=0.008) combined with chemotherapy (p=0.009) were the factors that extended PFS, and combined chemotherapy (p=0.040, HR=3.052, 95% CI 1.052- 8.858) was an independent prognostic factor.
Conclusions:
AM has good therapeutic efficacy in treating aNSCLC patients after chemotherapy failure. The side effects can be controlled and it is worth testing it in large-scale clinical studies.
Insights
Apatinib mesylate shows good efficacy in advanced non-small cell lung cancer patients who failed chemotherapy. Side effects are manageable, warranting further large-scale clinical studies for this targeted therapy.
Area of Science:
- Oncology
- Pharmacology
Background:
- Advanced non-small cell lung cancer (aNSCLC) presents significant treatment challenges, particularly after failure of standard chemotherapy.
- Targeted therapies are crucial for improving outcomes in patients with wild or unknown epidermal growth factor receptor (w/nEGFR) mutations.
Purpose of the Study:
- To evaluate the efficacy and safety of apatinib mesylate (AM) as a treatment for advanced non-small cell lung cancer (aNSCLC) in patients with wild or unknown EGFR status.
- To assess progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) of AM in this patient population.
Main Methods:
- A total of 34 patients with w/nEGFR-aNSCLC who had previously failed chemotherapy were enrolled.
- Patients received oral apatinib mesylate (425 mg/day) as primary treatment.
- Progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events were monitored.
Main Results:
- In 30 evaluable cases, the median PFS was 3.75 months, with an ORR of 20% and a DCR of 73.33%.
- Common adverse reactions included hypertension (52.94%), hand-foot syndrome (52.94%), proteinuria (44.12%), and fatigue (41.18%).
- ECOG performance status 0-1 and prior chemotherapy were identified as factors extending PFS, with combined chemotherapy being an independent prognostic factor.
Conclusions:
- Apatinib mesylate demonstrates good therapeutic efficacy in aNSCLC patients post-chemotherapy failure.
- The observed side effects are controllable, suggesting AM's potential as a treatment option.
- Further large-scale clinical studies are warranted to confirm these findings.
Related Concept Videos
01:11Observational Studies
There are three types of observational studies – Prospective, retrospective, and cross-sectional.
Prospective Study
Prospective studies, also known as longitudinal or cohort studies, are carried out by collecting future data from groups sharing similar characteristics. One...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:21Testing a Claim about Mean: Unknown Population SD
Estimating a population mean requires the samples to be approximately normally distributed. The data should be collected from the randomly selected samples having no sampling bias. There is no specific requirement for sample size. But if the sample size is less than 30, and we don't know the population standard deviation, a different approach is used;...
02:30Naturalistic Observations
01:37Energy to Drive Translocation
Generally, polypeptides are unfolded by two distinct...
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...